AKT1 and prostate carcinoma: The AKT and ERK pathway has been demonstrated to be required for androgen receptor (AR) activation in prostate cancer, in which PS-ITC (isothiocyanate) conjugate inhibits AKT, ERK, AR, and their downstream targets, ultimately leading to apoptosis and growth arrest in prostate cancer cells [110].